Abcam, ab313856, Anti-Influenza B Virus Neuraminidase antibody [HL1476] - BSA and Azide free

Size: 100µL
Anti-Influenza B Virus Neuraminidase antibody [HL1476] - BSA and Azide free (ab313856) is a rabbit recombinant monoclonal antibody provided in a PBS only buffer for easy conjugation detecting Influenza B Virus Neuraminidase in Western Blot, IHC-P, ICC/IF . - BSA, sodium azide, and glycerol-free for easy conjugation - Recombinant format for unrivalled batch-batch consistency
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:HL1476,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Influenza B,
Applications:WB, IHC-P, ICC/IFSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.

Product details:
What is this antibody validated in?
Anti-Influenza B Virus Neuraminidase antibody [HL1476] - BSA and Azide free (ab313856) is a rabbit recombinant monoclonal antibody and is validated for use in Western Blot (WB), Immunohistochemistry (IHC-P), Immunocytochemistry/immunofluorescence (ICC/IF) in Influenza B samples.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Aliquoting information-Upon delivery aliquot

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Influenza B Virus Neuraminidase also known as Influenza B NA is an enzyme important for the viral life cycle. This protein has an approximate molecular mass of 60 kDa and is expressed on the surface of the Influenza B virus. Neuraminidase facilitates the release of virions from infected cells by cleaving sialic acid residues aiding viral spread. It acts as a tetramer forming a homotetrameric structure which is essential for its enzymatic activity.
Biological function summary
The neuraminidase functions as part of the viral replication process. By cleaving sialic acid it prevents viral aggregation at the host cell surface ensuring efficient viral dissemination. This activity complements hemagglutinin another glycoprotein on the viral surface which binds to sialic acid on host cells to initiate infection. Together these proteins orchestrate the infection process marking the structural and functional complexity of the virus.
Pathways
Neuraminidase plays an integral role in the viral lifecycle pathway of the Influenza B virus. It closely interacts with the HA/NA balance where hemagglutinin (HA) binding necessitates subsequent neuraminidase activity to liberate progeny virions. This interaction is critical for maintaining the balance of viral attachment and release during infection influencing the overall efficiency of viral propagation.
The neuraminidase of the Influenza B virus is a significant target in antiviral drug design particularly in relation to influenza infections. Drugs like oseltamivir target neuraminidase to block its activity reducing viral spread and severity of infection. Furthermore the activity of neuraminidase is associated with resistance mutations influencing the effectiveness of antiviral treatment therefore posing significant challenges in combating influenza outbreaks.